Constitutive overexpression of muscarinic receptors leads to vagal hyperreactivity

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Livolsi, Angelo ^a   Niederhoffer, Nathalie ^a   Dali Youcef, Nassim ^a,b   Mokni, Walid ^a,b,c   Zorn, Catherine Olexa ^a   Gies, Jean Pierre ^a   Marcellin, Luc ^b   Feldman, Josiane ^a   Bousquet, Pascal ^a,b,c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Hô pitaux Universitaires   (France)

^c Université de Strasbourg   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; MESSENGER RNA; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PHENYLEPHRINE; ACHE PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MUSCARINIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC RISK; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RABBIT; RECEPTOR DENSITY; VAGUS NERVE STIMULATION; ANIMAL; CYTOLOGY; DISEASE MODEL; DNA SEQUENCE; GENE EXPRESSION REGULATION; HEART MUSCLE; HUMAN; METABOLISM; MONONUCLEAR CELL; NEWBORN; PATHOLOGY; SUDDEN INFANT DEATH SYNDROME; VAGUS NERVE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ACETYLCHOLINESTERASE; ANIMALS; BRADYCARDIA; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; INFANT, NEWBORN; LEUKOCYTES, MONONUCLEAR; MYOCARDIUM; PHENYLEPHRINE; RABBITS; RECEPTORS, MUSCARINIC; SEQUENCE ANALYSIS, DNA; SUDDEN INFANT DEATH; VAGUS NERVE;

EID: 78650990014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015618     Document Type: Article

References (32)

1. Livolsi A, Niederhoffer N, Dali-Youcef N, Rambaud C, Olexa C, et al. (2010) Cardiac muscarinic receptor overexpression in sudden infant death syndrome. PLoS One 5: e9464.
2. Shojaei-Brosseau T, Bonaïti-Pellie C, Lyonnet S, Feingold J, Lucet V (2003) Vagal overactivity: a risk factor of sudden infant death syndrome? Arch Dis Child 88: 88.
3. Edner A, Katz-Salamon M, Lagercrantz H, Ericson M, Milerad J (2000) Heart rate variability in infants with apparent life-threatening events. Acta Paediatr 89: 1326-1329.
4. Béchir M, Binggeli C, Corti R, Chenevard R, Spieker L, et al. (2003) Dysfunctional baroreflex regulation of sympathetic nerve activity in patients with vasovagal syncope. Circulation 107: 1620-1625.
5. Piccirillo G, Naso C, Moiseè A, Lionetti M, Nocco M, et al. (2004) Heart rate and blood pressure variability in subjects with vasovagal syncope. Clin Sci (Lond) 107: 55-61.
6. Vaddadi G, Lambert E, Corcoran S, Esler M (2007) Postural syncope: mechanisms and management. Med J Aust 187: 299-304.
7. Wilde A, Wieling W (2007) Vasovagal syncope or ventricular fibrillation. Your diagnosis better be accurate. Clin Auton Res 17: 203-205.
8. Ganzeboom K, Mairuhu G, Reitsma J, Linzer M, Wieling W, et al. (2006) Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol 17: 1172-1176.
9. Ganzeboom K, Colman N, Reitsma J, Shen W, Wieling W (2003) Prevalence and triggers of syncope in medical students. Am J Cardiol 91: 1006-1008, A1008.
10. Maron B (2003) Sudden death in young athletes. N Engl J Med 349: 1064-1075.
11. Engel G (1978) Psychologic stress, vasodepressor (vasovagal) syncope, and sudden death. Ann Intern Med 89: 403-412.
12. Livolsi A, Feldman J, Feingold J, Weiss L, Alembik Y, et al. (2002) First model of spontaneous vagal hyperreactivity and its mode of genetic transmission. Circulation 106: 2301-2304.
13. Gies J, Bertrand C, Vanderheyden P, Waeldele F, Dumont P, et al. (1989) Characterization of muscarinic receptors in human, guinea pig and rat lung. J Pharmacol Exp Ther 250: 309-315.
14. Haddad E, Landry Y, Gies J (1991) Muscarinic receptor subtypes in guinea pig airways. Am J Physiol 261: L327-333.
15. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
16. Wang Z, Shi H, Wang H (2004) Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 142: 395-408.
17. st edition. Br J Pharmacol 141 Suppl 1: S1-126.
18. Livak K, Schmittgen T (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Ellman G, Courtney K, Andres VJ, Feather-Stone R (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
20. Wang H, Han H, Zhang L, Shi H, Schram G, et al. (2001) Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol 59: 1029-1036.
21. Hellgren I, Mustafa A, Riazi M, Suliman I, Sylvén C, et al. (2000) Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol Life Sci 57: 175-180.
22. Willmy-Matthes P, Leineweber K, Wangemann T, Silber R, Brodde O (2003) Existence of functional M3-muscarinic receptors in the human heart. NaunynSchmiedebergs Arch Pharmacol 368: 316-319.
23. Shi H, Wang H, Wang Z (1999) Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts. Mol Pharmacol 55: 497-507.
24. Shi H, Wang H, Yang B, Xu D, Wang Z (2004) The M3 receptor-mediated K(+) current (IKM3), a G(q) protein-coupled K(+) channel. J Biol Chem 279: 21774-21778.
25. Chemnitius J, Haselmeyer K, Gonska B, Kreuzer H, Zech R (1997) Mipafox differential inhibition assay for heart muscle cholinesterases: substrate specificity and inhibition of three isoenzymes by physostigmine and quinidine. Gen Pharmacol 28: 567-575.
26. Dalefield R, Oehme F (1999) The presence of a muscarinic receptor on canine erythrocyte membranes. Gen Pharmacol 32: 341-344.
27. Carvalho F, Mesquita R, Martins-Silva J, Saldanha C (2004) Acetylcholine and choline effects on erythrocyte nitrite and nitrate levels. J Appl Toxicol 24: 419-427.
28. Smith P, Zhang C, Wang J, Chew S, Zhang M, et al. (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15: 2490-2508.
29. Cartegni L, Wang J, Zhu Z, Zhang M, Krainer A (2003) ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 31: 3568-3571.
30. Blencowe B (2000) Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 25: 106-110.
31. Adamia S, Reichert A, Kuppusamy H, Kriangkum J, Ghosh A, et al. (2008) Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood 112: 5111-5121.
32. Wei J, Sulakhe P (1978) Regional and subcellular distribution of myocardial muscarinic cholinergic receptors. Eur J Pharmacol 52: 235-238.